Functional and Cognitive Impairment in Patients with Relapsing–Remitting Multiple Sclerosis: Cognitive Tests and Plasma Neurofilament Light Chain Levels
Elīna Polunosika(Riga East University Hospital), Guntis Karelis(NeuroRx Research (Canada)), Henrik Zetterberg(University of Wisconsin–Madison), Renārs Erts(University of Latvia), Kaj Blennow(Sahlgrenska University Hospital), Arta Akmene(Riga East University Hospital), Joel Simrén(University of Gothenburg), Nikita Klimovskis(Riga Stradiņš University), Daina Pastare(Riga East University Hospital)
Cited by 1
Related Papers
Defeating Alzheimer's disease and other dementias: a priority for European science and society
|The Lancet Neurology|2016|1.7k
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
|JAMA Neurology|2021|627
Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report
|Nature Medicine|2019|606
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
|Alzheimer s & Dementia|2022|589
A multicentre validation study of the diagnostic value of plasma neurofilament light
|Nature Communications|2021|554